News and Trends 27 Jun 2023 Actimed Therapeutics raises £5M to advance lead program for cancer cachexia Actimed Therapeutics Ltd, a U.K.-based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has raised more than £5 million ($6.4 million) in an over-subscribed Series A financing round. The investment will support the development of the Actimed pipeline, including S-pindolol benzoate, with preparations […] June 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2023 Laying the foundation for the future of personalized treatment? In the evolving world of precision medicine, the need for methods that can measure biomolecules with supreme accuracy and specificity is paramount. Recognizing this, Yan Xu of the Graduate School of Engineering at Osaka Metropolitan University in Japan, and his international research team, say they have made a great stride in this direction. They have […] June 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2023 AbbVie takes step forward in Europe with migraine drug AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral […] June 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 New disease characteristic seen as NMD Pharma reports Charcot-Marie-Tooth results NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, has presented results from ESTABLISH1, an observational study of neuromuscular function in patients with the inherited neurological conditions Charcot-Marie-Tooth (CMT) types 1 and 2. The results were revealed in a poster presentation at the Peripheral Nerve Society Annual […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 Breakthrough treatment for skin infections? A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 European Coalition for Access to Comprehensive Genomic Profiling launched The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, have launched the European Coalition for Access to Comprehensive Genomic Profiling (ECGP), to improve cancer care through increased routine clinical access and reimbursement of Comprehensive Genomic Profiling (CGP) in Europe. CGP is a method of testing tumors that […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 Sarepta gets approval for first gene therapy for Duchenne muscular dystrophy Sarepta Therapeutics, Inc. has announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an Adeno-associated virus (AAV)-based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 SandboxAQ launches new division to boost drug development After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Alchemab Therapeutics unveils Alzheimer’s candidate Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Ovarian cancer study finds key genes for potential treatments New study is increasing knowledge of why some women with the most lethal form of ovarian cancer respond much better to treatment than others. Researchers at Imperial College London in the U.K. have confirmed that the tumors of some women with high-grade serious ovarian cancer (HGSOC) contain a type of lymphoid tissue – known as […] June 22, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 FDA approves type 2 diabetes drug for children 10 and older The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2023 Nanobody company Attovia Therapeutics launches with $60M Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, have launched Attovia Therapeutics, a company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email